BioLife Solutions Price Target Raised to $30.00/Share From $27.00 by HC Wainwright & Co.
BioLife Solutions Is Maintained at Buy by HC Wainwright & Co.
BioLife Solutions Analyst Ratings
Maxim Group Maintains BioLife Solutions(BLFS.US) With Buy Rating, Maintains Target Price $34
H.C. Wainwright Maintains BioLife Solutions(BLFS.US) With Buy Rating, Raises Target Price to $30
Lake Street Maintains BioLife Solutions(BLFS.US) With Buy Rating, Maintains Target Price $30
Craig-Hallum Maintains BioLife Solutions(BLFS.US) With Buy Rating, Announces Target Price $32
Analysts Offer Insights on Healthcare Companies: TG Therapeutics (TGTX), BioLife Solutions (BLFS) and Surgery Partners (SGRY)
Benchmark Co. Maintains BioLife Solutions(BLFS.US) With Buy Rating, Maintains Target Price $30
TD Cowen Maintains BioLife Solutions(BLFS.US) With Buy Rating, Maintains Target Price $31
BioLife Solutions: Promising Financial Outlook and Strategic Positioning Justify Buy Rating
Craig-Hallum Maintains BioLife Solutions(BLFS.US) With Buy Rating
Craig-Hallum Keeps Their Buy Rating on BioLife Solutions (BLFS)
Craig-Hallum Maintains BioLife Solutions(BLFS.US) With Buy Rating
Lake Street Maintains BioLife Solutions(BLFS.US) With Buy Rating, Maintains Target Price $30
Craig-Hallum Maintains BioLife Solutions(BLFS.US) With Buy Rating
Northland Securities Maintains BioLife Solutions(BLFS.US) With Buy Rating, Raises Target Price to $31
Maxim Group Initiates BioLife Solutions(BLFS.US) With Buy Rating, Announces Target Price $34
BioLife Solns Analyst Ratings
Maxim Group Maintains BioLife Solutions(BLFS.US) With Buy Rating, Raises Target Price to $34